Practical, honest health journalism - pharmaceutical policy, clinical evidence, and the realities of medical access.
European pharmaceutical surveillance has produced substantial data about the actual scale and composition of counterfeit medication in consumer markets. What the data shows about which medications are most commonly counterfeited, how the supply chains work, and what practical consumer guidance emerges.
Which tadalafil dosing schedule actually works better for men over 45? Three-year cohort study data has clarified the choice between daily low-dose and on-demand higher-dose tadalafil protocols. What the actual clinical outcomes show and how to think about the choice for individual patients.
The TRAVERSE trial results have substantially clarified the clinical picture around TRT for men with clinical hypogonadism. What the data actually shows two years post-publication, how it should shape prescribing decisions, and what remains unresolved despite the substantial evidence advance.
A comprehensive review of the past 18 months of clinical data on erectile dysfunction, hormonal wellness, and pharmaceutical interventions. What works, what doesn't, and what the mainstream media isn't telling you.
Why the same molecule sells for $18 or $2. A market analysis of erectile dysfunction generics from India, Serbia, and the global supply chains that determine what you actually get.